Five Prime, GlaxoSmithKline deal

GlaxoSmithKline gave a 180-day notice to terminate a 2011 deal with Five Prime granting the pharma exclusive rights in the U.S., EU and Canada to develop and commercialize cancer candidate FP-1039. The original deal was between Five Prime and Human Genome Sciences Inc., which GSK acquired in 2012.

In January, GSK and Five Prime stopped enrolling patients with squamous non-small cell lung cancer (NSCLC) in an open-label study but continued to enroll mesothelioma patients. At the time, Five Prime said it hoped to reacquire rights to the fibroblast growth factor (FGF) ligand trap based on early mesothelioma data from the trial. GSK will transfer rights back to Five Prime, which will continue the study. ...